엑소좀 시장 - 시장 규모, 전망, 임상 시험 및 동향(2026년)

Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The cargo contained within exosomes can offer prognostic information for range of diseases-including cardiovascular, renal, neurodegenerative, and metabolic diseases-as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient’s response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

Additionally, there has also been tremendous growth in the number of exosome scientific publications, patents (intellectual property), and clinical trials in recent years.

Finally, exosomes are now being used in a diverse range of applications, including:

• 1. Diagnostics: Biomarkers for disease detection
• 2. Regenerative Medicine: Cell-free therapeutics being leveraged for tissue repair, wound healing, and reversal of disease
• 3. Drug Delivery: Vehicles for targeted therapeutic delivery
• 4. Research Products: Tools for studying cell communication and disease mechanisms
• 5. Dermatology and Aesthetics: Wound repair, skin rejuvenation, anti-aging treatments, and hair restoration.
• 6. Emerging Applications: Exosome vaccines, immunotherapies (leveraging exosomes from activated T cells or NK cells), veterinary medicine, agricultural applications (plant-derived exosomes), and beyond.

Global Exosome Market

The science is scaling fast. Today, researchers have catalogued more than 119,000 exosome-associated protein entries in dedicated databases like ExoCarta, and a single exosome can carry anywhere from a few dozen to 1,000–2,000 distinct proteins reflecting the physiological state of its parent cell. As of June 2026, PubMed.gov indexes 44,211 published papers on exosome research - up from just 282 in 2010, with annual output alone reaching 6,304 papers in 2025. Asia/Pacific now produces 52% of global exosome publications, followed by Europe (28%) and the United States (20%), though the U.S. retains the highest citation impact and remains the top country for clinical translation.

Harvard University leads all institutions by publication volume and citation impact, with Karolinska Institutet a leading center for therapeutic applications. Patent activity has grown just as sharply, from 8 filings in 2000 to 1,921 in 2025, with the United States (22,120 total filings), WIPO, and China as the leading jurisdictions. Clinical development has kept pace: 579 exosome-related trials are now registered globally, led by the United States (149 trials) and China (138), with oncology representing roughly 30% of the therapeutic pipeline.

No exosome-based therapeutic or diagnostic has yet received full FDA approval, but that is poised to change. One of the most closely watched programs in this space is Capricor Therapeutics’ Deramiocel (CAP-1002) for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. Deramiocel is administered as a cell therapy, allogeneic cardiosphere-derived cells (CDCs), but its proposed mechanism of action is exosome-mediated: the CDCs work by secreting exosomes that shift macrophages from a pro-inflammatory to a healing phenotype. The FDA granted Deramiocel Priority Review, but a July 2026 advisory committee voted 9–3 against recommending approval for the original cardiomyopathy indication. In response, Capricor submitted additional Phase 3 HOPE-3 data and narrowed its proposed indication to preservation of upper-limb function; the FDA has since extended its target action (PDUFA) date to November 22, 2026.

On the diagnostics side, two tests already operate as CLIA-certified Laboratory Developed Tests: the ExoDx Prostate IntelliScore (EPI), now under MDxHealth following its 2025 divestiture from Bio-Techne, and ExoTRU, a kidney transplant-rejection assay from Bio-Techne/Thermo Fisher Scientific.

The industry is also seeing intensifying investment and dealmaking activity. Venture capital funding into exosome-focused companies has mobilized close to $600 million since 2010, with roughly $155 million raised between 2023 and mid-2026 alone across notable rounds such as EXO Biologics’ $18.7 million Series A, Annie Aesthetic Holdings’ $65 million Series B, and PranaX Corporation’s $17 million Series A. Strategic acquisitions are consolidating the space as larger players move to secure diagnostic and technology platforms - most notably MDxHealth’s purchase of Exosome Diagnostics (and its ExoDx Prostate test) from Bio-Techne for $15 million, ExoCoBio’s acquisition of majority ownership in BENEV to expand global aesthetic distribution, and Evox Therapeutics’ acquisition of Codiak Biosciences’ engineered exosome technology platform.

Meanwhile, licensing and partnership activity between biopharma and exosome innovators - including deals involving Capricor Therapeutics, RION, Lonza, and Evox Therapeutics - increasingly features milestone-based structures reaching up to $1 billion, reflecting how major pharmaceutical players are moving to lock in proprietary delivery platforms and manufacturing capacity ahead of costly late-stage clinical trials.

Global Exosome Market Report

To characterize this rapidly maturing industry, BioInformant has released this global strategic report - now spanning 384 pages - exploring demand across these distinct market segments:

• Research Products
• Development & Manufacturing
• Diagnostics, Therapeutics
• Medical Aesthetics
• Ready-to-Use Exosomes

Collectively, these segments are already generating substantial global revenue and are on track for dramatic multi-year expansion, with the report detailing precise figures and forecasts for each segment through 2034. Research Products remains the largest segment currently, while Medical Aesthetics ranks a close second and is the fastest-growing segment in immediate revenue terms. Diagnostics is the fastest-growing segment by percentage, expanding at an especially steep rate off a small current base, while Therapeutics is poised for a sharp inflection point as the first approved products reach the market. Geographically, North America commands the largest share of global revenue by a wide margin, followed by Europe, with Asia-Pacific close behind - led overwhelmingly by China’s outsized share of the regional total.

The report features in-depth profiles of 135 global competitors spanning the exosome marketplace, from research-tool suppliers like Thermo Fisher Scientific, QIAGEN, and Bio-Techne to clinical-stage innovators like Capricor Therapeutics, Evox Therapeutics, and Aruna Bio, and aesthetic-market leaders like ExoCoBio, Rion Aesthetics, and Kimera Labs.

Today the exosome industry is witnessing:

• A surging number of scientific papers investigating exosomes and their applications
• Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
• Swelling appetite among investors for exosome technology
• An increasingly competitive IP environment
• A diverse range of co-development partnerships
• Proliferating numbers of exosome competitors in all major life science markets worldwide

This report reveals:

• The clinical pipeline for exosome therapeutics and diagnostics
• Clinical trial activity by phase, geography, application, and sponsor
• Patent landscape trends by jurisdiction, assignee, and domain of innovation
• Industry M&A activity, financing events, and strategic partnerships
• Detailed profiles of competitors from across the global exosome marketplace
• Market size determinations across six segments, with forecasts through 2034
• Key industry trends, competitive opportunities, and future outlook

With the competitive nature of this global market, you don’t have the time to do the research yourself. Claim this report to become immediately informed, without sacrificing hours of research or missing critical opportunities.

About BioInformant

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 19+ years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, AABB, and Vogue Magazine. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill.

The content within this report was compiled using a diverse range of sources, as described in this Research Methodology.